Results 21 to 30 of about 99,309 (305)

Poor Compliance Makes Treatment of Latent Tuberculosis Infection Unsatisfactory

Journal of Primary Care & Community Health, 2012
Objectives: The recommended treatment for latent tuberculosis infection is isoniazid for 9 months, but this regimen has a low completion rate. The authors wanted to compare treatment with isoniazid and treatment with isoniazid and rifampin in the typical
Panupong Larppanichpoonphol, Satish Bagdure, Hoda Mojazi Amiri, Kenneth Nugent   +3 more
doaj   +1 more source

Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS

Molecules, 2022
Isoniazid and its metabolites are potentially associated with hepatotoxicity and treatment outcomes in patients who receive antituberculosis (TB) therapy.
Nguyen Ky Anh, Pham My Tung, Min Jung Kim, Nguyen Phuoc Long, Yong-Soon Cho, Dong-Hyun Kim, Jae-Gook Shin   +6 more
doaj   +1 more source

Dual antibiotherapy of tuberculosis mediated by inhalable locust bean gum microparticles [PDF]

, 2017
Despite the existence of effective oral therapy, tuberculosis remains a deadly pathology, namely because of bacterial resistance and incompliance with treatments.
Alves, Ana D., Buttini, Francesca, Cavaco, Joana S., Grenha, Ana, Guerreiro, Filipa, Pontes, Jorge Filipe, Rodrigues, Susana, Rosa Da Costa, Ana   +7 more
core   +1 more source

Phenotypic low-level isoniazid resistance as a marker to predict ethionamide resistance in Mycobacterium tuberculosis

International Journal of Mycobacteriology, 2017
Background: Tuberculosis is one of the most prevalent diseases in Pakistan. Pakistan has the highest burden of MDR-TB in the Eastern Mediterranean region. Ethionamide is an anti-tuberculous drug frequently used to treat MDR-TB.
Salima Qamar, Joveria Q Farooqi, Kausar Jabeen, Rumina Hasan   +3 more
doaj   +1 more source

Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawi

Frontiers in Public Health, 2020
Background: Pellagra is caused by niacin (vitamin B3) deficiency and manifested by a distinctive dermatitis. Isoniazid is critical for treating tuberculosis globally and is a component of most regimens to prevent tuberculosis. Isoniazid may contribute to
Scott A. Nabity, Kelvin Mponda, Steve Gutreuter, Diya Surie, Anne Williams, Anne Williams, Andrea J. Sharma, Elizabeth R. Schnaubelt, Rebekah E. Marshall, Hannah L. Kirking, Suzgo B. Zimba, Joram L. Sunguti, Laphiod Chisuwo, Mabvuto J. Chiwaula, Jesse F. Gregory, Robin da Silva, Michael Odo, Andreas Jahn, Thokozani Kalua, Rose Nyirenda, Belaineh Girma, James Mpunga, Nicole Buono, Alice Maida, Evelyn J. Kim, Laurence J. Gunde, Tigest F. Mekonnen, Andrew F. Auld, Adamson S. Muula, John E. Oeltmann   +29 more
doaj   +1 more source

The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats

Brazilian Journal of Medical and Biological Research, 2021
It is known that the combined use of antibiotics, such as isoniazid and rifampicin, in the treatment of tuberculosis causes oxidative kidney damage. The aim of this study was to biochemically and histopathologically investigate the effect of lycopene on ...
F. Bedir, H. Kocaturk, O. Turangezli, E. Sener, S. Akyuz, F.B. Ozgeris, B. Dabanlioglu, H. Suleyman, D. Altuner, B. Suleyman   +9 more
doaj   +1 more source

Breast tuberculosis in Northeast Iran: Review of 22 cases [PDF]

, 2014
Background: Breast tuberculosis (breast TB) is an extremely rare disease, so case reviews are also rare.Methods: This study is a retrospective review of patients with breast TB who were treated between 2002 and 2012 at the Health Center of Gorgan City ...
Khodabakhshi, B., Mehravar, F.
core   +2 more sources

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

Emerging Infectious Diseases, 2006
In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation.
Maria Elvira Balcells, Sara L. Thomas, Peter Godfrey-Faussett, Alison D. Grant   +3 more
doaj   +1 more source

Inhalable fucoidan microparticles combining two antitubercular drugs with potential application in pulmonary tuberculosis therapy [PDF]

, 2018
The pulmonary delivery of antitubercular drugs is a promising approach to treat lung tuberculosis. This strategy not only allows targeting the infected organ instantly, it can also reduce the systemic adverse effects of the antibiotics. In light of that,
Ana Grenha, Ana Rosa da Costa, Buttini, Francesca Buttini, Ludmylla Cunha, M Faleiro, Stefaniak-Vidarsson, Susana Rodrigues   +7 more
core   +2 more sources

Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon

The Pan African Medical Journal, 2020
INTRODUCTION: It is unclear what the optimal treatment regimen for previously treated patients with rifampicin-susceptible isoniazid resistant tuberculosis should be. Conflicting evidence exists as to the effectiveness of the WHO standardized category II
Christopher Kuaban, Louise Daniele Ingrid Toukam, Melissa Sander   +2 more
doaj   +1 more source